Ambrx And BMS Join For Drug Conjugates | Chemical & Engineering News
Volume 91 Issue 19 | p. 25 | Concentrates
Issue Date: May 13, 2013

Ambrx And BMS Join For Drug Conjugates

Department: Business
Keywords: biopharmaceuticals, antibody drug conjugates

Ambrx and Bristol-Myers Squibb have agreed to discover and develop antibody-drug conjugates using Ambrx’ protein medicinal chemistry technology. In exchange for commercial rights, BMS will supply Ambrx $15 million up front, R&D funding, and up to $97 million per product upon reaching certain milestones. The two companies have worked together since September 2011 on the discovery of biologic drugs. As a result of that work, BMS is currently developing a potential diabetes drug and a heart failure treatment.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment